Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C

Liver International

Volumn 33, Issue 1, 2013, Pages 94-103

  Pascarella, Stéphanie ^a   Clément, Sophie ^b   Dill, Michael T ^c   Conzelmann, Stéphanie ^a   Lagging, Martin ^d   Missale, Gabriele ^e   Neumann, Avidan U ^f   Pawlotsky, Jean Michel ^g   Zeuzem, Stefan ^h   Rubbia Brandt, Laura ^b   Bochud, Pierre Yves ⁱ   Negro, Francesco ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f BAR ILAN UNIVERSITY   (Israel)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cirrhosis; HCV; Hepatitis C; RVR; SOCS; SVR

Indexed keywords

GLUCOSE; INSULIN; MESSENGER RNA; PEGINTERFERON ALPHA; PEPTIDES AND PROTEINS; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 7; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; DISEASE COURSE; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LINEAR MODELS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; ODDS RATIO; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870846460     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12031     Document Type: Article

References (41)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
3. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009; 29(Suppl 1): 15-8.
4. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
6. Naka T, Fujimoto M, Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci 1999; 24: 394-8.
7. Gadina M, Hilton D, Johnston JA, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001; 13: 363-73.
8. Kim KA, Lin W, Tai AW, et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50: 705-11.
9. Miyaaki H, Ichikawa T, Nakao K, et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res 2009; 39: 850-5.
10. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-35.
11. Persico M, Capasso M, Russo R, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2008; 57: 507-15.
12. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-15.
13. Huang Y, Feld JJ, Sapp RK, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733-44.
14. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-9.
15. Imanaka K, Tamura S, Fukui K, et al. Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy. J Viral Hepat 2005; 12: 130-8.
16. Pascarella S, Clément S, Guilloux K, et al. Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. J Med Virol 2011; 83: 1005-15.
17. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
18. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-7.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
21. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
22. Sarrazin C, Shiffman ML, Hadziyannis SJ, et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010; 52: 832-8.
23. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis 2011; 31: 115-27.
24. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
25. Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697-706.
26. Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010; 138: 932-41 e931-3.
27. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012; 56S1: S56-65.
28. Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38-46.
29. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-24.
30. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-44.
31. Zhang Y, Li P, Li G, et al. The mechanism of how anti-IL-18 prevents concanavalin-A-induced hepatic fibrosis on a mouse model. J Surg Res 2007; 142: 175-83.
32. Cheng KS, Tang HL, Chou FT, Dhiman RK, Chawla Y. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1105-10.
33. Sharma A, Chakraborti A, Das A, et al. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 2009; 128: e514-22.
34. Campbell JS, Prichard L, Schaper F, et al. Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest 2001; 107: 1285-92.
35. Saxena NK, Titus MA, Ding X, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004; 18: 1612-4.
36. Hora C, Negro F, Leandro G, et al. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int 2008; 28: 370-6.
37. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004; 11: 91-6.
38. Testa R, Franceschini R, Giannini E, et al. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000; 33: 33-7.
39. Ogata H, Chinen T, Yoshida T, et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 2006; 25: 2520-30.
40. Okochi O, Hibi K, Sakai M, et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 2003; 9: 5295-8.
41. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-28.